Cancer immunotherapy aims to harness the immune system to recognize and destroy cancer cells more effectively. Research focuses on understanding how tumors evade immune attack and on designing treatments that restore or boost immune activity.

One major approach is immune checkpoint inhibition. Tumors often exploit inhibitory molecules such as PD 1, PD L1 and CTLA 4 to switch off T cells. Drugs that block these checkpoints can reinvigorate T cells and produce durable responses in cancers like melanoma, lung cancer and kidney cancer. However, only a fraction of patients benefit, so current work seeks biomarkers that predict response and combination strategies that broaden effectiveness.

Another strategy is adoptive cell therapy, particularly CAR T cells. Here, a patient’s T cells are engineered to express receptors that recognize specific tumor antigens, then expanded and reinfused. This has shown striking success in certain leukemias and lymphomas, but challenges include severe immune side effects, limited efficacy in solid tumors and antigen escape. Researchers are refining CAR designs, targeting multiple antigens and improving T cell persistence.

Cancer vaccines represent a further avenue. Therapeutic vaccines attempt to prime the immune system against tumor associated or patient specific neoantigens. Early clinical results show immune activation, and ongoing studies test combinations with checkpoint inhibitors to enhance efficacy.

Across all modalities, a central theme is personalization. Tumors differ widely between patients, so tailoring immunotherapies to each cancer’s mutations, microenvironment and immune profile is a major goal. Future directions include integrating genomics, single cell analyses and advanced computational models to guide individualized treatment and optimize combinations while limiting toxicity.